8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin

Table 1 Tumorsphere formation ability of CD133⁺ cells derived from the MHCC97 cell line (mean ± SD, n = 3)

Cell line	Spheroid number/2 × 103 cells		Volume of spheroid (μm3)
	Parental cells	CD133+ cells	Parental cells	CD133+ cells
MHCC97	61 ± 26	167 ± 31a	153 ± 31	397 ± 45a

^aP <0.05 vs parental MHCC97 cells.

Table 2 Tumorigenicity of CD133⁺ sphere forming cell derived from MHCC97 cells in Balb/c-nu mice

Cell type	No. inoculated cells	Tumor incidence1	Latency (d)2
Parental cells	1 × 104	0/4	-
	1 × 105	0/4	-
	1 × 106	4/4	39
CD133+ SFCs	2 × 103	3/4	31
	1 × 104	4/4	23
	1 × 105	4/4	8

¹Number of tumors detected/number of injections;

²Approximate number of days from tumor cell injection to appearance of a tumor. SFC: Sphere forming cells.

Table 3 Effects of 8-bromo-7-methoxychrysin on growth of secondary tumors in Balb/c-nu mice inoculated with tumor cells obtained from primary xenografts

Time (d)	Tumor incidence1		Volume (mm3)
	Control	BrMC-treated group	Control	BrMC-treated group
1	0/12	0/12	-	-
3	0/12	0/12	-	-
6	4/12	0/12	28 ± 12	-
12	9/12	0/12	134 ± 29	-
15	12/12	3/12	321 ± 63	16 ± 8
18	12/12	3/12	532 ± 96	33 ± 16
21	8/8	2/8	351 ± 67	23 ± 13
24	8/8	2/8	593 ± 131	32 ± 24
27	4/4	1/4	264 ± 91	54
30	4/4	1/4	387 ± 114	67
33	4/4	1/4	567 ± 126	82

¹Number of tumors detected/number of injections. BrMC: 8-bromo-7-methoxychrysin